

# Journal of Materials Chemistry B

Materials for biology and medicine

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: Y. Han, Q. Jiang, Y. Li, M. Wang, T. Fan, M. Liu, Q. Ke, H. Xu and Z. Yi, *J. Mater. Chem. B*, 2019, DOI: 10.1039/C9TB01327J.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1 An aligned porous electrospun fibrous scaffold  
2 embedded *Asiatic acid* for accelerating diabetic  
3 wound healing

4 Yiming Han <sup>a, ‡</sup>, Yuqi Jiang <sup>b, ‡</sup>, You Li <sup>a</sup>, Minna Wang <sup>a</sup>, Tingting Fan <sup>a</sup>, Mingyao  
5 Liu <sup>a</sup>, Qinfei Ke <sup>b</sup>, He Xu <sup>b, \*</sup>, Zhengfang Yi <sup>a, c, \*</sup>

6 <sup>a</sup> East China Normal University and Shanghai Fengxian District Central Hospital Joint  
7 Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology,  
8 Institute of Biomedical Sciences and School of Life Sciences, East China Normal  
9 University, 200241 Shanghai, China.

10 <sup>b</sup> College of Chemistry and Materials Sciences, Shanghai Normal University, No. 100  
11 Guilin Road, Shanghai 200234, China

12 <sup>c</sup> Shanghai Engineering Research Center of Molecular Therapeutics and New Drug  
13 Development, School of Chemistry and Molecular Engineering, East China Normal  
14 University, Shanghai 200062, China

15 Yiming Han and Yuqi Jiang are co-first authors.

16 \*Corresponding authors.

17 E-mail addresses: zfyi@bio.ecnu.edu.cn (Z. Yi), xuhe@shnu.edu.cn (H. Xu)

18

19

20

1 **Abstract**

2 The diabetic non-healing wound is one of the most common complications of  
3 diabetics. The long-term stimulus of oxidant-stress, inflammation and infection caused  
4 by the hyperglycemia microenvironment in the wound site always leads to the delayed  
5 healing process of the diabetic wound. To address this issue, in this study, we prepared  
6 an Asiatic acid (AA)-embedded aligned porous poly (L-lactic acid) (PLLA) electrospun  
7 fibrous scaffold (AA-PL) for accelerating diabetic wound healing. The results showed  
8 that the electrospun fibers with nano-pores on the surfaces aligned in a single direction,  
9 while the AA was well embedded in the fibers and can be continuously released from  
10 the fibers. The *in vitro* results revealed that the AA-PL scaffolds can effectively  
11 alleviate the H<sub>2</sub>O<sub>2</sub>-induced oxidant-stress damage to HaCat cells and down-regulate the  
12 LPS-induced pro-inflammatory cytokines (IL-1 $\beta$ , TNF- $\alpha$ , IL6) gene expression in  
13 RAW 264.7 macrophage cells. Moreover, the growth of *E. coli* and *S. aureus* could be  
14 inhibited by the AA-PL scaffolds. The *in vivo* study further demonstrated that, the AA-  
15 PL scaffolds can accelerate the re-epithelization, angiogenesis and extracellular matrix  
16 (ECM) formation of the wound by relieving the high oxidative stress, inflammation and  
17 infection in the diabetic wound site. This study suggests that the combination of  
18 hierarchical structures (nanopores on the aligned fibers) with the controllable released  
19 AA from the scaffolds is an efficient and innovative strategy for the treatment of  
20 diabetic non-healing wounds.

21 **Keywords:** Electrospun nanofibrous scaffold, aligned porous structure, Asiatic acid,  
22 anti-inflammation, diabetic wound healing

23

24

## 1 1. Introduction

2 Chronic non-healing wound is one of the most common complications of diabetic  
3 patients. As the long-term stimulus of oxidant-stress, inflammation and infection  
4 caused by the hyperglycemia microenvironment in the wound site, it leads to the  
5 delayed re-epithelialization, insufficient vascular lesions and extracellular matrix  
6 (ECM) synthesis of the diabetic wounds. Therefore, it is of great significance to  
7 develop an effective strategy to treat diabetic wounds through anti-oxidative stress anti-  
8 inflammation or anti-bacteria. [1, 2]

9 *Centella asiatica* is a kind of Chinese medicinal herb, and the application of its  
10 extraction in wound healing, skin burns, and scar formation had been widely studied.  
11 [3, 4] Asiatic acid (AA), has been proven to be the most active substance in the  
12 extractions of *Centella asiatica* and it can effectively promote the gene expression of  
13 TGF- $\beta$  (Transforming growth factor- $\beta$ ), VEGF (Vascular endothelial growth factor)  
14 and FGFs (Fibroblast Growth Factors) expression in fibroblasts. [5] Most importantly,  
15 AA has been demonstrated to have a significant anti-oxidant and anti-inflammatory  
16 efficiency in various inflammatory disease models. [6, 7] Beyond that, the anti-bacterial  
17 activity of AA has also been verified in many strains. [8] These advantages make AA be  
18 a potential drug for treating diabetic wounds. However, an overdose of AA would may  
19 have potential side effects such as cytotoxicity and neurotoxicity. [9] Therefore, to  
20 develop a controlled-release system with low by-effect is of great importance, which  
21 would not only provide sustained and appropriate delivery of AA with an appropriate  
22 dose but also increase the utility of AA during the wound healing process. [10, 11]

23 Electrospinning is one of the most advantageous technique for preparing skin  
24 tissue engineering scaffolds. [12] The micro/nano-scaled fibers in electrospun scaffold  
25 can not only provide mechanical support for cells adhesion but also promote cell growth  
26 with improved bio-guided activity at the wound site by simulating the ECM  
27 microenvironment. [13] Normally, the electrospun nanofibers are collected randomly

1 and the scaffold exhibits a nonwoven structure. In recent years, some researchers have  
2 successfully fabricated aligned electrospun scaffolds with the nanofibers arranged in a  
3 single direction. Compared with the random nanofibers, the scaffold with aligned  
4 nanofibrous structure presents greater potential for skin tissue reconstruction, and the  
5 “contact-guided” effect of aligned nanofibers on cells can relatively shorten the time  
6 for wound healing. [14, 15] In addition, previous studies have proved that the aligned  
7 scaffold could improve the type I collagen expression in the Dural fibroblast cells, and  
8 compared with the random scaffolds, the collagen fibers exhibited a higher degree of  
9 organization on the aligned scaffolds. [16] Hence, the aligned nanofibrous scaffolds can  
10 be a favorable candidate for diabetic wound healing. Moreover, the electrospun fibrous  
11 matrices have been widely explored in the biologic delivery systems due to its high  
12 drug loading efficiency, so it is an advisable strategy to employ the aligned electrospun  
13 scaffolds as a controlled-release system to load AA, and the composite scaffolds will  
14 play as a multi-function platform for the effective treatment of diabetic wound.

15 Meanwhile, it is worth noting that the diabetic non-healing wounds are mainly  
16 caused by the failed inflammatory regression in the early stage of wound healing, which  
17 ultimately leads to long-term inflammation at the wound sites. Hence, through releasing  
18 AA to achieve anti-oxidative stress and anti-inflammatory in the early stage of wound  
19 healing will largely improve the therapeutic efficiency of AA. Exactly, the nanofibers  
20 with porous surface structure which can not only increase the specific surface area to  
21 benefit the cell adhesion, but also can shorten the drug release cycle and promote the  
22 AA work in the early stage of diabetic wound healing. [17]

23 In this study, we developed an aligned porous electrospun fibrous scaffold with a  
24 local AA delivery system for accelerating diabetic wound healing. The anti-oxidant  
25 stress, anti-inflammation and anti-bacterial effects of aligned porous AA-embedded  
26 PLLA electrospun scaffold (AA-PL) *in vitro* were evaluated. Finally, the stimulatory  
27 effect of the AA-PL scaffolds on the wound closure, inflammation responses, re-

1 epithelialization ratio, angiogenesis and ECM remodeling in the STZ-induced diabetes  
2 wound model were verified.

## 3 **2. Materials and methods**

### 4 **2.1 Materials**

5 Poly (L-lactic acid) (PLLA, Mw = 300 kDa) was purchased from Jinan Daigang  
6 Biomaterial Co., Ltd. (Shandong, China). Dichloromethane (DCM) was supplied by  
7 Aladdin Reagent Co. (Shanghai, China). Asiatic acid (AA) was purchased from Selleck  
8 Reagent Co. (Houston, Texas, USA). All materials in this study were used as received  
9 without any further purification.

10 Immortalized human keratinocytes HaCaTs were purchased from the Type Culture  
11 Collection of the Chinese Academy of Sciences, Shanghai, China. Mouse mononuclear  
12 macrophage cell line RAW 264.7 were purchased from the cell bank, American Type  
13 Culture Collection (ATCC, Manassas, VA, USA).

### 14 **2.2 Preparation of the aligned porous AA-PL scaffolds**

15 The aligned porous fibrous PLLA (PL) scaffold containing different contents of  
16 AA (0%, 10%, 30%) were prepared by electrospinning. 0.6 g of PLLA was dissolved  
17 in 4.9 mL DCM, and then 0.1 mL AA solution (0  $\mu$ M, 5  $\mu$ M, 15  $\mu$ M in ethanol) was  
18 added to the PLLA/DCM solution with continuous stirring to obtain homogeneous  
19 solutions. The electrospinning process was carried out using a TEADFS-103  
20 electrospinning apparatus (Beijing Technova Technology Co., Ltd). In a typical  
21 procedure, the applied electric voltage was 8 kV, the solution feed rate was 0.02  
22 mL/min, the distance between the spinneret and the grounded drum was 8 cm, the  
23 rotating speed of the collecting drum was 800 r/min and the collecting time for all  
24 samples was fixed for 3.5 hours.

25 The experiments were conducted at room temperature, and the relative humidity

1 was around 50 RH%. All of the as-prepared electrospun scaffolds were vacuum-dried  
2 for 24 hours to completely remove the residual solvent prior to further characterization.  
3 In this study, the composite electrospun scaffolds with different contents of AA were  
4 named as PL, 10 AA-PL and 30 AA-PL, respectively.

### 5 **2.3 Morphologies, composition and surface wettability characterizations of the** 6 **aligned porous AA-PL scaffolds**

7 The morphologies and microstructures of the PLLA, 10 AA-PL and 30 AA-PL  
8 scaffolds were observed by scanning electron microscopy (FE-SEM, HitachiS-4800,  
9 CanScan). The hydrophilicity of electrospun scaffolds were investigated by testing the  
10 water contact angle on the surfaces (Kruss GmbH DSA 100 Mk 2).

### 11 **2.4 AA release profile of the AA-PL scaffolds *in vitro***

12 0.2 g 10 AA-PL and 30 AA-PL scaffolds were immersed into 5 mL PBS (pH =  
13 7.4) at 37 °C in a shaker with the speed of 80 rpm/min, respectively. At each defined  
14 time point, 1mL of the release medium was collected for detection and replaced with  
15 an equal volume of fresh PBS. The amount of released AA in the collected solution was  
16 determined using a UV-vis spectrophotometer (Epoch, BioTek Instruments, Gene Co.  
17 Ltd., USA).

### 18 **2.5 Cell culture**

19 The HaCat and RAW 264.7 were purchased from Sciencell Research Laboratories  
20 (San Diego, CA, USA). The HaCat cells were cultured in complete RPMI-1640 cell  
21 medium (1640, Gibco, USA) supplemented with 5% fetal bovine serum (FBS, Gibco,  
22 USA) and 1% penicillin/streptomycin (P/S, Sciencell, USA). RAW cells were cultured  
23 in Dulbecco's Modified Eagle Medium (DMEM, ThermoFisher, USA) supplemented  
24 with 5% FBS (Gibco, USA) and 1% P/S (Sciencell, USA). All the cell lines were

1 cultured in a humidified 37 °C / 5% CO<sub>2</sub> incubator and the medium was replaced every  
2 2 days.

### 3 **2.6 IL-1 $\beta$ , TNF- $\alpha$ and IL6 gene expression level in the LPS-induced inflammation** 4 **model when co-cultured with AA-PL scaffold**

5 To verified the anti-inflammation effect of AA-PL scaffolds, we stimulated RAW  
6 264.7 macrophage cells with bacterial lipopolysaccharide (LPS) to promote the  
7 expression of proinflammatory cytokines, which is the most commonly inflammation  
8 model *in vitro*.<sup>[19]</sup> To detect the expression of proinflammatory cytokine, RAW 264.7  
9 macrophage cells were seeded on the sterile PL, 10 AA-PL, 30 AA-PL nanofibrous  
10 scaffolds with a density of 1 $\times$ 10<sup>4</sup> cells /100  $\mu$ L in 6-well plates. The non-treated (BL)  
11 and LPS-treated groups with no scaffold added (Ctrl) were set as the two reference  
12 groups. After cultured at 37 °C / 5% CO<sub>2</sub> incubator for 24 hours, the cells of Ctrl, 10  
13 AA-PL and 30 AA-PL treated groups were stimulated with 100  $\mu$ g/mL of LPS for 6  
14 hours. Finally, the cells were washed with PBS for three times carefully, and then the  
15 total RNA of cells were collected with Trizol (Invitrogen, Waltham, MA, USA)  
16 according the manufacturer's protocol.

17 The gene expression of proinflammatory cytokines IL-1 $\beta$ , TNF- $\alpha$  and IL6 was  
18 evaluated by quantitative real-time polymerase chain reaction (Q-RT-PCR) according  
19 to the manufacturer's protocols. The total RNA (1  $\mu$ g) was collected and reversed into  
20 cDNA by using Prime Script<sup>TM</sup> RT Master Mix (TakaraBio Inc., Shiga, Japan) at 37 °C  
21 for 30 min and 85 °C for 10 seconds. Subsequently, Q-RT-PCR was conducted by using  
22 SYBR Green detection reagent (TakaraBio Inc. Shiga, Japan). In this study, all primers  
23 were found in the Primer Bank and synthesized by Genewiz. Co (Shanghai, China), the  
24 specificity of the primers was confirmed before being used. The primer sequences used  
25 for all PCR reactions were shown in Table 1.  $\beta$ -Actin was used as the housekeeping  
26 gene. The expression of each gene was normalized relative to  $\beta$ -Actin and the results



1 were quantified relative to the corresponding gene expression of the PLLA group,  
2 which was standardized to 1.

### 3 **2.7 Proliferation of HaCat cells treated with high-oxidation stress when co-** 4 **cultured with AA-PL scaffolds**

5 Before the cell experiments, all scaffolds were cut into round shaped pieces which  
6 could exactly fit the size of culture plates, then the scaffolds were sterilized by UV over  
7 3 hours.

8 HaCat cells were seeded on the PLLA, 10 AA-PL and 30 AA-PL scaffolds with a  
9 density of  $1 \times 10^4$  cells / 200  $\mu$ L per well in 48-well plates and cultured at 37 °C / 5%  
10 CO<sub>2</sub> incubator for 24 hours. To simulate the high oxidative stress environment at the  
11 diabetic wound site, HaCat cells in all groups (Ctrl, PL, 10 AA-PL and 30 AA-PL) were  
12 treated with 500  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 2 hours, [18] the HaCat cells cultured with no scaffold  
13 were considered as control groups (Ctrl). In addition, to verify the high oxidative stress  
14 effect of the H<sub>2</sub>O<sub>2</sub> on the cell behavior, the non-treated HaCat cells were cultured as the  
15 blank groups (BL).

16 To evaluate the cell viability in different groups, after being cultured for 24 hours,  
17 the H<sub>2</sub>O<sub>2</sub>-treated or non-treated HaCat cells in all four groups were stained with a  
18 LIVE/DEAD® Viability Kit (ThermoFisher, USA) according to the supplier's  
19 procedure. The cell viability and morphology were observed and photographed using  
20 an inverted fluorescence microscope (Leica TCS SP8, Germany), then quantified the  
21 number of Live/Dead cell in 10 $\times$  magnification with Image J, and calculated the ratio  
22 of Live/dead cells by the below formation:

23 
$$\text{Ratio of Live/dead cells} = \text{Numbers of live cells} / \text{Total number of cells}$$

24 To evaluate the cell proliferation in different groups, after incubating the H<sub>2</sub>O<sub>2</sub>-  
25 treated HaCat in 37 °C / 5% CO<sub>2</sub> for 2 hours, the cell proliferation was detected by MTS  
26 assay. The culture medium was replaced with 160  $\mu$ L fresh DEME medium and 40  $\mu$ L

1 MTS in each well, then the cells were incubated in a 37 °C / 5% CO<sub>2</sub> incubator for 1.5  
2 hours. The absorbance value of samples was measured at 490 nm with a microplate  
3 reader (Epoch, BIO-TEK, USA).

#### 4 **2.8 Antibacterial effect of the PLLA, 10 AA-PL, 30 AA-PL scaffolds**

5 0.1g sterilized PL, 10 AA-PL, 30 AA-PL scaffolds were soaked in 1 mL LB  
6 medium for 48 hours, then 10<sup>8</sup> CFU *E. coli* (ATCC 8739) and *S. aureus* (ATCC 29213)  
7 were cultured with the extract solution of PL, 10 AA-PL, 30 AA-PL and 25 ug/mL  
8 Penicillin for 24 hours. Then, diluted the bacterial solution to 1×10<sup>6</sup> times and coated  
9 10 µL diluted bacterial solution on the Agar-LB solid medium. After incubated in a 37  
10 °C incubator for 24 hours, the colonies in each group were observed and photographed  
11 by high resolution camera (Canon, Japan), then calculated the bacterial concentration  
12 of each treated group by Image J.

#### 13 **2.9 Establishment of the non-contractile diabetic wound model**

14 50 males C57BL/6J mice (7-8 weeks age) were purchased from Shanghai Jinlake  
15 Experimental Animal Center. The experimental was performed in the specific pathogen  
16 free (SPF) environment and all experimental procedures involving mice were given  
17 approval by the Animal Investigation Committee of the Institute of Biomedical  
18 Sciences and School of Life Sciences, East China Normal University.

19 The streptozotocin (STZ) (Sigma, USA) - induced diabetic model was established  
20 as previously described, [20] STZ was diluted with a citric acid buffer (pH = 4.2-4.5),  
21 and the mice were injected intraperitoneally with a dose of 40 mg/kg body weight per  
22 day for 5 consecutive days. After 10 days, the blood glucose of the mice was detected  
23 with glucose meters device (Accu-Chek Performa) and the mice were considered as  
24 diabetics if the non-fasted glycaemia was higher than 20 mM. Mice (n = 12/group) were  
25 randomly allocated to the Ctrl, PL, 10 AA-PL and 30 AA-PL treated groups according  
26 to the glucose levels.

1 The diabetic mice (17-18 weeks age) were anesthetized with inhaled 5% isoflurane  
2 and shaved the dorsal hair of mice before surgery. A full-thickness circular skin wounds  
3 with the diameter of 8 mm were created on the dorsum of each mice and fixed with a  
4 silicone loop (silicone sheet, 3M, USA) (internal diameter = 8 mm, external diameter  
5 = 15 mm) to prevent contraction of wounds, thus simulating the wound healing process  
6 of diabetes. [21] The wounds were treated with different kinds of to-be-tested scaffolds  
7 (PL, 10 AA-PL, 30 AA-PL) or non-treated (Ctrl). All the wounds in the four groups  
8 were covered with the medical grade bandages (HAINUO, China) and breathable films  
9 (Tegaderm, 3M, USA) after surgery. For wound healing assay, the wound areas were  
10 photographed on day 0, 3, 5, 7, 11, 13, 15 and calculated by Image J. The wound healing  
11 rate was calculated according to the following formula:

$$A_N \text{ rate (\%)} = (A_0 - A_N) / A_0 \times 100\%$$

12  
13 Where  $A_0$  is the initial wound area ( $N = 0$ ) and  $A_N$  is the wound area at day  $N$   
14 ( $N \geq 1$ ).

## 15 **2.10 Q-RT-PCR, immunohistochemical and immunofluorescence analysis of the** 16 **wound tissues**

17 About five mice each group were sacrificed at day 7 and day 15 post-surgery, the  
18 skin tissue surrounding wound edges with the width of about 2 mm were collected for  
19 the Q-RT-PCR, immunohistochemical and immunofluorescence analysis.

20 The total RNA of re-epithelized skin tissue was extracted by Trizol (Invitrogen,  
21 Waltham, MA, USA), the gene expression of proinflammatory cytokine (IL-1 $\beta$ , TNF-  
22  $\alpha$ , IL-6) were detected by the method as described above.

23 For immunohistochemical analysis, the wound tissues were fixed by 4%  
24 paraformaldehyde for 48 h. Then, they were dehydrated with a graded series of ethanol  
25 (50%, 70%, 80%, 95% and 100%) and embedded in paraffin. The paraffin-embedded  
26 tissues were cut into slices with the thickness of 5  $\mu\text{m}$  and tiled on the glass slide.

1 To evaluate the re-epithelization, collagen deposition, inflammation and  
2 angiogenesis in the wound sites of different groups at day 7 and 15 post-operation, the  
3 sections were deparaffinized with dimethylbenzene and rehydrated with 100%, 95%,  
4 80% and 70% ethanol. IL6 immunohistochemical staining was performed for the  
5 evaluation of inflammation. The Masson trichrome staining was conducted to observe  
6 the re-epithelization and collagen deposition. The CD31 (Platelet endothelial cell  
7 adhesion molecule-1) immunofluorescence staining was performed to observe the  
8 angiogenesis. The Masson trichrome staining were conducted to evaluate the collagen  
9 distribution and density, collagen can be stained blue and epithelial or fibroblasts can  
10 be dyed red. We evaluated the collagen deposition in the wound tissues by calculated  
11 the percentage of collagen fibers area at 20 × magnification with Image J. The  
12 formation as below :

$$13 \quad \text{Collagen density (\%)} = \text{Area of collagen fibers} / \text{the total area} \times 100\%$$

14 All the experimental procedures were conducted according to the supplier's  
15 procedure.

16 Immunohistochemical and immunofluorescence staining was performed just as the  
17 follow steps: The samples were boiled in sodium citrate buffer (pH = 6.5) and then  
18 incubated with IL6 antibody (Abcam, USA) or CD31 antibody (Abcam, USA) at 4 °C  
19 for overnight. The sections were incubated with secondary antibodies for 2 hours at  
20 room temperature. Adding 5 mg/mL 4', 6-diamidino-2-phenylindole (DAPI) solution  
21 to the tissue sections for counterstaining cell nuclei. The images were obtained using  
22 an optical microscope (Leica Confocal microscope, Germerny). The collagen area and  
23 CD31-positive vessel number were measured manually by Image J software.

## 24 **2.11 Statistical analysis**

25 Three independent experiments were carried out and at least three samples per each  
26 test were taken for statistical analysis. Data were presented means ± standard error.

1 Statistical differences among more than two groups were calculated using one-way  
2 ANOVA firstly and then a Student's t-test program was further conducted to evaluate  
3 the significant difference between each two groups. Differences were considered  
4 significant when  $P < 0.05(*)$ ,  $P < 0.01(**)$  or  $P < 0.001(***)$ .

### 5 **3. Results**

#### 6 **3.1 Characterization of the aligned porous AA-PL scaffolds**

7 The macroscopic appearance of the AA-PL electrospun scaffolds were shown in  
8 Figure S1, the aligned porous AA-PL scaffolds were fabricated with poly (L-lactic acid),  
9 so it exhibited as white and smooth membrane, and consisted of the aligned electrospun  
10 fibers evenly. The microscopic morphologies of PLLA electrospun scaffolds with  
11 different contents of AA were shown in Figure 1, the nanofibers in all the three scaffolds  
12 were aligned in a single direction and exhibited well-organized topological structures  
13 (Figure 1 A<sub>1</sub>-C<sub>1</sub>). The magnified SEM images in Figure 1 A<sub>2</sub>-C<sub>2</sub> further revealed that  
14 there were uniform nanopores on the surface of each fiber in all the three scaffolds.

15 The hydrophilicity of the PLLA, 10 AA-PL and 30 AA-PL scaffolds were  
16 investigated by water contact angle (WCA) measurement. As shown in Figure 1 A<sub>3</sub>-C<sub>3</sub>,  
17 the three scaffolds exhibited a similar surface hydrophilic behavior and the WCA values  
18 of the PLLA, 10 AA-PL, 30 AA-PL scaffolds were all about 90°. The hydrophilicity of  
19 the scaffolds is improved comparing with pure PLLA polymer, which is more  
20 conducive to cell adhesion and growth on the surface of the AA-PL scaffolds. [22]

#### 21 **3.2 The cumulative release of AA from aligned porous AA-PL scaffolds**

22 AA has a remarkable absorbance at 197 nm ultraviolet rays (Figure 2A). As  
23 observed in Figure 2B, the UV absorbance curve of the extract solution of PL, 10 AA-  
24 PL and 30 AA-PL scaffolds also exhibited a remarkable absorbance at 197 nm, it  
25 coincided with the absorbance curve of AA. This result identified that the AA had been  
26 successfully incorporated into the aligned porous electrospun scaffolds. As Figure 2B

1 shown, the cumulative release AA reach to 48  $\mu\text{g}$  from 10 AA-PL and 149  $\mu\text{g}$  from 30  
2 AA-PL, there were approximately 70% of loaded AA released from 10 AA-PL and 30  
3 AA-PL scaffolds (Figure 2C). AA was released rapidly from 10AA-PL and 30 AA-PL  
4 scaffolds during the first 48 hours and can be continuously released for 7 days.

### 5 **3.3 The anti-inflammation and anti-oxidant stress effects of the aligned porous** 6 **AA-PL scaffolds *in vitro***

7 Diabetes non-healing wounds are characterized by the long-term inflammation.  
8 Here, the common inflammatory model used *in vitro* was constructed by the stimulation  
9 of the RAW 264.7 macrophage cells with bacterial lipopolysaccharide (LPS). [23] The  
10 expression of pro-inflammatory cytokines in RAW 264.7 macrophage cells were  
11 detected by Q-RT-PCR. As shown in Figure 3A-C, the gene expression levels of IL-  
12  $1\beta$ , TNF- $\alpha$  and IL6 in RAW 264.7 macrophage cells were significantly increased after  
13 the stimulation by LPS. However, the gene expression levels of above genes in RAW  
14 264.7 macrophage cells were effectively down-regulated in both the 10 AA-PL and 30  
15 AA-PL treated groups, especially for that in the 30 AA-PL group, which showed the  
16 lowest gene expression of pro-inflammatory cytokines.

17 To simulate the high oxidant-stress environment of diabetic wound site, the HaCat  
18 cells were treated with 500  $\mu\text{m}$   $\text{H}_2\text{O}_2$  after co-cultured with PL, 10 AA-PL, 30 AA-PL  
19 scaffolds for 24 hours, then the cells viability were observed by Live/Dead staining and  
20 cells proliferation were detected by MTS assay to evaluate the anti-oxidant effect of  
21 scaffolds under high oxidative stress. Compared with the non-treated HaCat (BL)  
22 shown in Figure 3D(a), after being treated with  $\text{H}_2\text{O}_2$ , there was an obvious shrinkage  
23 in cell morphology and quite a lot of dead cells appeared in the view (Figure 3D(b)).  
24 Similarly, the  $\text{H}_2\text{O}_2$ -treated HaCat cells co-cultured with the PLLA scaffolds also  
25 showed obvious shrinkage morphologies (Figure 3D(c)). However, the  $\text{H}_2\text{O}_2$ -induced  
26 oxidant-stress damage of the HaCat cells were effectively alleviated, and the number  
27 of viable cells was increased in the AA-PL scaffolds treated groups. Especially for the  
28 30 AA-PL treated group (Figure 3D(e)), the scaffolds significantly improved the

1 growth and viability of cells. The result (Figure 3E) of proliferation assay showed that  
2 the number of HaCat cells on the 10 AA-PL and 30 AA-PL scaffolds were significantly  
3 higher than that of the Ctrl group and PL treated group, indicating the positive effect  
4 on the anti-oxidation stress of the 10 AA-PL and 30 AA-PL scaffolds.

### 5 **3.4 The aligned porous AA-PL scaffolds inhibits *S. aureus* and *E. coli* growth.**

6 The antibacterial property is a crucial factor for an ideal skin tissue engineering  
7 scaffold and the high antibacterial activity of scaffold can significantly accelerate the  
8 tissue repair process. [24] The minimum inhibitory concentration (MIC) of AA were in  
9 the range of 20-40  $\mu\text{g/ml}$ , and its minimum bactericidal concentration (MBC) were in  
10 the range of 32-52  $\mu\text{g/ml}$ . The antibacterial effective concentration of AA is comparable  
11 to t penicillin, which is the most commonly used antibiotic in clinical. [8] Therefore, the  
12 inhibitory effect of Penicillin and AA-PL scaffolds on *E. coli* (ATCC 8739) and *S.*  
13 *aureus* (ATCC 29213) were evaluated. As Figure 4 shown, compared with the PLLA  
14 treated group, Penicillin (25  $\mu\text{g/mL}$ ), 10 AA-PL and 30 AA-PL can significantly inhibit  
15 the growth of bacteria, especially 30AA-PL exhibits optimal antibacterial effect. The  
16 antibacterial effect of 30 AA-PL is significantly better than that of Penicillin (25  
17  $\mu\text{g/mL}$ ), it implied that AA-PL scaffolds may be an alternative strategy for resistant  
18 infections of wound in clinically.

### 19 **3.5 The aligned porous AA-PL scaffolds accelerate diabetic wound healing *in vivo***

20 The wound healing assay on diabetic mice was performed to further verify the  
21 effect of AA-PL scaffolds on the wound healing efficiency *in vivo*. To simulate the low  
22 contractility feature of the diabetic wounds in human being, a non-contractile full-  
23 thickness diabetic wound model had been constructed in this work and the experimental  
24 procedure was shown in Figure 5A. As shown in Figure 5B, the wound area in Ctrl  
25 (non-treated), PL, 10 AA-PL and 30 AA-PL groups became smaller with increasing  
26 time, while the wound healing rate of the 30 AA-PL scaffolds treated group was

1 significantly higher than that of the other three groups (Ctrl, PL and 10 AA-PL) from  
2 day 3. At day 7 after operation, the healing rates of 30 AA-PL groups was 63.01%,  
3 while that of the Ctrl, PL and 10 AA-PL groups were 20.01%, 24.96%, 50.21%,  
4 respectively. At the day 14, the wound healing rate of 30 AA-PL group was 97.37%,  
5 whereas that of the Ctrl, PL, 10 AA-PL were 50.25%, 66.08%, 94.49% respectively.  
6 All above results indicated that the 30 AA-PL scaffolds exhibited the highest wound  
7 healing rate among all the treated groups.

### 8 **3.6 The anti-inflammation effect of the aligned porous AA-PL scaffolds during** 9 **the diabetic wound healing**

10 Long-term inflammation is an important cause of non-healing diabetic wound. IL6  
11 is a pro-inflammatory cytokine which can be used as a biomarker of inflammation. In  
12 this work, the IL6 immunohistochemical staining was performed to evaluate the  
13 inflammation level in the wound sites. As observed in Figure 6A, the distribution of  
14 IL6-positive cells (brown) were much more densely in the wound tissue of Ctrl, PL and  
15 10 AA-PL treated groups. In contrast, IL-6 positive cells were significantly reduced in  
16 the 30 AA-PL treated groups both at day 7 and 15 after surgery. Especially at day 15,  
17 the IL 6 positive cells were significantly decreased in the wound tissues of 30 AA-PL  
18 treated group and the architecture of normal skin tissue could be obviously observed,  
19 suggesting the great anti-inflammatory effect of 30 AA-PL scaffolds during diabetic  
20 wound healing. While there were abundant IL 6 positive cells gathered at the wound  
21 edges of the Ctrl, PL and 10 AA-PL treated groups. To further verify the anti-  
22 inflammation effect of 30 AA-PL scaffolds, the gene expression level of IL-1 $\beta$ , TNF- $\alpha$   
23 and IL6 in wound tissue at day 7 (Figure 6 B-D) and day 15 (Figure 6 E-G) were  
24 evaluated by Q-RT-PCR. As shown in Figure 6 B-G, the gene expression levels of  
25 proinflammatory cytokines: IL1 $\beta$ , TNF- $\alpha$ , and IL6 in the wound tissue of the 30 AA-  
26 PL treated groups were obviously the lowest among all treated groups.



### 3.7 The aligned porous AA-PL scaffolds accelerate re-epithelialization of diabetic wound

Re-epithelialization is a crucial stage in the process of diabetic wound healing, in which stage epithelial keratinocytes will proliferate and migrate from the wound edge to the center of wound tissues, forming a complete epithelial layer. [25] As shown in Figure 7A, the newly formed epithelium layers in 30 AA-PL treated groups were significantly increased than that of the Ctrl, PL, 10 AA-PL treated groups at day 7, and the wound tissue in 30 AA-PL treated group formed much more continuously intact epithelial layer at day 15, indicating a better promoting efficiency on re-epithelialization of 30 AA-PL scaffolds than that of the Ctrl, PL and 10 AA-PL scaffolds. The quantitative analysis results of re-epithelialization were shown in Figure 7B-C revealed that, the re-epithelialization ratio of 30 AA-PL treated groups (64.22%) was significantly higher than that of the Ctrl (8.54%), PL (34.17%), and 10 AA-PL (58.25%) treated groups at day 7. At day 15 after surgery, the re-epithelialization ratio of 30 AA-PL treated group was 94.71%, while that of the Ctrl, PL, 10 AA-PL treated groups were 51.13%, 64.41%, 77.65%, respectively.

### 3.8 The effect of the aligned porous AA-PL scaffolds on the angiogenesis in the diabetic wound *in vivo*.

The early 3-7 day of wound healing is an important stage for formatting granulation tissue which consisted of fibroblasts and neovascular. In order to verify the angiogenesis during the diabetic wound healing process, the CD31 immunofluorescence staining was performed to observe the neovascularization in the wound tissue at 7 days after surgery. As shown in Figure 8A and B, the number of CD31 positive vessels in the wound tissues of the 10 AA-PL and 30 AA-PL treated groups were obviously higher than that of the Ctrl and PL treated group at day 7. The above results showed that the 10 AA-PL and 30 AA-PL scaffolds promoted angiogenesis during diabetes wound healing.

### 1 **3.9 The effect of the aligned porous AA-PL scaffolds on ECM formation *in vivo***

2 As shown in Figure 9A, compared with the Ctrl group, more collagen fibers (ECM  
3 remodeling marker, stained with blue) were observed in the PLLA, 10 AA-PL and 30  
4 AA-PL treated groups. Especially, the collagen fibers in the wound tissues of 30 AA-  
5 PL treated group were more interweaved and tended to form more intensive and orderly  
6 structures at day 15 after surgery. The quantitative analysis of the deposited collagen in  
7 the wound sites shown in Figure 9B demonstrated that the collagen deposition in 30  
8 AA-PL treated group (95.97%) was significantly higher than that in the Ctrl (62.15%),  
9 PL (75.94%) and 10 AA-PL (88.59%) treated groups. It implied a more advanced  
10 collagen deposition process in the 30 AA-PL treated groups.

## 11 **4. Discussion**

12 Previous studies have mainly focused on improving angiogenesis or antibacterial,  
13 as a single strategy for the treatment of diabetic non-healing wounds. [24-27] However,  
14 due to the complex pathological environment at the diabetic wound site, those  
15 efficiencies are limited. Since the most essential causes of the diabetic non-healing  
16 wounds are hyper oxidative stress, inflammation and infection, which were caused by  
17 the hyperglycemia microenvironment in wound sites, [28, 29] alleviating the oxidant-  
18 stress, inflammation and infection at the wound site will be an effective strategy for  
19 diabetic wound healing. [30] AA was proved to be a potential drug for diabetes by the  
20 antioxidant, anti-inflammatory and antibacterial efficiencies. In this study, AA was  
21 chosen as an active ingredient incorporated into an aligned porous composite PLLA  
22 scaffolds via electrospinning for highly efficient diabetic wound healing.

23 Since the aligned nanofibers have been proven to have significant impacts on  
24 directing the cellular alignment and migration by “contact guidance”, which could  
25 accelerate cells migrate from the edge to the center of wound, so the aligned nanofibers  
26 have advantage on preparing wound dressing. [31] What’s more, the porous surface of  
27 aligned nanofibers not only could enhance the surface roughness, which benefit for cell  
28 adhesion and proliferation; but also increase the effective surface area of membranes,

1 which conducive to drug loading and release continuously. Herein, we successfully  
2 fabricated an aligned PLLA electrospun scaffold as the drug-delivery system, Figure 1  
3 showed that the PLLA fibers in electrospun scaffolds were orderly aligned in a single  
4 direction, as a result of the combined effects of the electrostatic force in the electric  
5 field and the stretching force of the collecting drum during the electrospinning process.

6 Diabetic wound is characterized of the oxidant stress, prolonged inflammatory and  
7 infection caused by the hyperglycemia microenvironment, which will prevent the  
8 diabetic wound at prolonged inflammation phase transfer to the next proliferation phase.  
9 Hyperglycemia and extra-oxidative stress environment of wound sites impaired  
10 macrophage and neutrophils function result in the prolonged inflammation; the  
11 impaired keratinocyte cause delay re-epithelialization; impaired fibroblast and vascular  
12 endothelial cells lead the insufficient granulation tissue and ischemia. The  
13 hyperglycemia environment also makes the wound tissues more susceptible to be  
14 infected, further cause the chronic non-healing wound. Overall, the hyperglycemia and  
15 oxidative stress are the root causes of diabetic non-healing wounds. [32, 33]

16 In this study, to relieve those symptoms the early stage of wound healing and  
17 promote the transition of wound from inflammation to the proliferation phase, we have  
18 chosen *Asiatic acid* (AA), a Chinese herbal compound, which have the anti-oxidant,  
19 anti-inflammation and anti-bacteria effect, as a potential drug for diabetic wounds. The  
20 uniform nanopores with ellipse-like morphologies were generated on the surface of  
21 each fiber by using low boiling solvent during the electrospinning process, and these  
22 nanopores on the surfaces of fibers could facilitate the release of AA at the early stage  
23 of diabetes wound healing. As illustrated in Figure 2, AA was well embedded in the  
24 fibers and can be continuously released from 10 AA-PL and 30 AA-PL for 7 days,  
25 which could exactly meet the requirement of the early inflammation stage (3-7 days  
26 after trauma) during the diabetic wound healing. [34]

27 Macrophages is the foremost producer of pro-inflammatory cytokines IL-1 $\beta$ , TNF-  
28  $\alpha$ , IL-6 and VEGF, IGF-1 and TGF- $\beta$ , they are pivotal contributor both in diabetic and  
29 non-healing wound healing. [35-37] Usually, those cytokines and growth factors are  
30 increased in the early 3 days and decreased gradually after inflammation phase. While

1 in diabetes wound, pro-inflammatory cytokines sustain production continuously,  
2 caused the prolonged inflammation phase, it leads the extra-oxidant stress environment  
3 on the wound site, further impaired the angiogenic response, migration and proliferation  
4 of keratinocytes and fibroblast. [38, 39] Therefore, eliminating inflammation, it can  
5 effectively regulate the levels of cytokines and growth factors during wound healing. It  
6 has been reported that the expression of pro-inflammatory factors of macrophages is  
7 elevated when exposing in LPS stimuli, it usually triggered by activation of NF- $\kappa$ B.  
8 While AA may down-regulate NF- $\kappa$ B (nuclear factor- $\kappa$ B) activation in RAW 264.7  
9 MACROPHAGE cells,[39] and further reduce proinflammation cytokines IL-1 $\beta$ , TNF-  
10  $\alpha$  and IL6 production to attenuated the prolonged inflammation. In this work, the 10  
11 AA-PL and 30 AA-PL scaffolds have significantly down-regulated the high expression  
12 of pro-inflammatory cytokines IL-1 $\beta$ , TNF- $\alpha$ , IL6 (Figure 3A-C) in LPS-induced  
13 macrophage inflammation model *in vitro*. In STZ-induced diabetes non-contraction  
14 wound model, with the increasing content of AA, the IL-6 expression in the diabetes  
15 wound sites had been reduced in the 10 AA-PL and 30 AA-PL treated groups.

16 The prolonged inflammation could cause high oxidative stress microenvironment  
17 at wound sites, it especially induces the injury, dysfunction, and apoptosis of  
18 keratinocyte, further result in the delayed re-epithelialization. [29, 40] H<sub>2</sub>O<sub>2</sub> could  
19 inducing excessive ROS (Reactive oxygen species) in cells, damage cell membranes  
20 and mitochondria, further leading cell apoptosis, so we treated the HaCat cells with  
21 H<sub>2</sub>O<sub>2</sub> to simulate the supra-physiological oxidative stress microenvironment in diabetic  
22 wound sites *in vitro*. Previous study has proven that AA could prevent oxidative stress  
23 and apoptosis by maintaining membrane integrity and ATP production. [41] Therefore,  
24 we evaluated the protect effect of AA-PL scaffolds on HaCat under oxidative stress, As  
25 Figure 3D-E showed, the AA-PL exhibited significant protect effect on morphology  
26 and proliferation of HaCat cells which damaged by H<sub>2</sub>O<sub>2</sub> induced supra-oxidant stress  
27 *in vitro* and accelerated re-epithelialization during diabetes wound healing (Figure 7)  
28 *in vivo*.

29 Infection caused by hyperglycemia microenvironment in the wound sites was  
30 another main barrier for diabetes wound healing. Previous studies have proved that AA

1 could destroy the biofilm of the bacterial community and the cell membrane of  
2 individual cells, which cause bacterial nuclear leakage to achieve antibacterial purposes  
3 dose-dependently. [42-44] Consistent with previous researches, 30 AA-PL scaffolds also  
4 exhibited the best anti-bacterial effect among all treated groups (Figure 4).

5 Sum up the above results, we can ensure that the AA-PL scaffolds could release  
6 effective concentration of AA in the safe range, and exhibited great effect on anti-  
7 oxidative stress, anti-inflammation and anti-bacteria *in vitro*. To further verify the effect  
8 of AA-PL scaffolds on accelerating diabetes wound *in vivo*, and exploring that whether  
9 the aligned porous structure and released AA could improve non-healing wounds  
10 synergistically, the wound healing assay was performed in the STZ-induced diabetes  
11 non-contraction wound model. In accordance with the significant effect of AA-PL  
12 scaffolds *in vitro*, the diabetic wounds treated with AA-PL scaffolds showed higher  
13 wound healing rate as compared with that of the PLLA and Ctrl groups starting from  
14 the day 3 after surgery, especially for that of the 30 AA-PL scaffolds, which exhibited  
15 the highest wound healing rate (Figure 5) by down-regulating IL-1 $\beta$ , TNF- $\alpha$ , IL6 gene  
16 expression (Figure S2 and 6) and accelerating re-epithelialization (Figure 7),  
17 angiogenesis (Figure 8) and collagen deposition (Figure 9) in diabetes wound site. The  
18 underlying mechanism may relate to the anti-oxidative stress, anti-inflammation and  
19 antibacterial effect of AA-PL, which are conducive to alleviate those symptoms of  
20 diabetes non-healing wound, further promoting the non-healing wound at long-term  
21 inflammation phase transferred into the proliferation phase during diabetes wound  
22 healing. [45, 46] The overall microenvironmental change at the wound sites induced by  
23 AA-PL scaffold promoted faster healing process for diabetic wounds. What's more,  
24 consistent with the previous study, the aligned PL scaffolds can shorten the time of  
25 wound healing by facilitating the migration of keratinocytes and fibroblasts from the  
26 periphery of the wound to the center, and significantly promote re-epithelization and  
27 collagen formation during the process of wound healing. [47, 48] Hence, in this work, the  
28 aligned porous structure of AA-PL indeed provided bio-guidance and mechanical  
29 support to facilitate diabetes wound healing. In conclusion, AA-PL scaffolds provided  
30 a suitable environment for wound healing through the dual advantages of AA release

1 and aligned porous structure, which can be used as an excellent scaffold for promoting  
2 diabetic wound healing.

### 3 **5. Conclusion**

4 In this study, an Asiatic acid (AA)-embedded aligned porous poly ( $\text{L}$ -lactic acid)  
5 (PLLA) electrospun fibrous scaffold had been successfully fabricated for accelerating  
6 diabetic wound healing. AA was embedded in aligned porous electrospun fibrous  
7 scaffolds, and could sustain release from the AA-PL scaffolds. Especially, the 30 AA-  
8 PL scaffolds could effectively alleviate the oxidant-stress damage to HaCat cells and  
9 down-regulate gene expression of pro-inflammatory cytokines, as well as anti-bacteria  
10 *in vitro*. The *in vivo* study further evidenced that 30 AA-PL exhibited an excellent effect  
11 on accelerating re-epithelization, angiogenesis and ECM formation during diabetes  
12 wound healing in diabetic mice. Above results suggest that the combination of  
13 hierarchical aligned structures with the controllable released AA from the scaffolds is  
14 an efficient and innovative strategy for the treatment of diabetic non-healing wounds  
15 and other types of skin injure.

### 16 **Acknowledgments**

17 This study was partially supported by National Natural Science Foundation of  
18 China (81472788, 81773204, 81330049, 81501597), National Key R&D Program of  
19 China (2018YFA0507000), Major State Basic Research Development Program of  
20 China (2015CB910400), and Innovation Program of Shanghai Municipal Education  
21 Commission (2017-01-07-00-05-E00011).

### 22 **Author contribution**

23 Yiming Han and Yuqi Jiang contributed equally to this work. Yiming Han, Yuqi Jiang,  
24 He Xu and Zhengfang Yi designated the idea of the present work. He Xu, Qinfei Ke,  
25 Mingyao Liu and Zhengfang Yi supervised the project and commented on the project.  
26 Yuqi Jiang and He Xu synthesized and characterized the AA-PL scaffolds, Yiming Han

1 performed *in vitro* experiments and *in vivo* experiments, analyzed the dates. You Li  
2 contributed to the anti-bacteria assay. Minna Wang and Tingting Fan were assist in  
3 completing diabetes wound healing experiments. Yiming Han wrote the manuscript.  
4 All the authors contributed to the discussion during the whole project.

## 5 Reference

- 6 [1] S.A. Eming, P. Martin, M. Tomic-Canic 2014 Wound repair and regeneration:  
7 Mechanisms, signaling, and translation, *Sci. Transl. Med.* **6** 1946-6242
- 8 [2] C.C. Lan, C.S. Wu, S.M. Huang, I.H. Wu, G.S. Chen 2013 High-glucose  
9 environment enhanced oxidative stress and increased interleukin-8 secretion from  
10 keratinocytes: new insights into impaired diabetic wound healing, *Diabetes.* **62** 2530-  
11 2538
- 12 [3] W. Bylka, P. Znajdek-Awizen, E. Studzinska-Sroka, A. Danczak-Pazdrowska, M.  
13 Brzezinska 2014 Centella asiatica in dermatology: an overview, *Phytother. Res.* **28**  
14 1117-1124
- 15 [4] Veeraya Paocharoen MD 2010 The efficacy and side effects of Oral Centella  
16 asiatica extract for wound healing promotion in diabetic wound patients. *J Med Assoc*  
17 *Thai.* **93** s166-s170
- 18 [5] Christopher D and Puziah Hashim 2003 Gene expression Changes in the human  
19 fibroblast induced by Centella asiatica Triterpenoids, *Planta Med.* **69** 725-732
- 20 [6] J.W. Lv, A. Sharma, T. Zhang, Y.C. Wu, X.T. Ding 2018 Pharmacological Review  
21 on Asiatic Acid and Its Derivatives: A Potential Compound, *Slas Technology.* **23** 111-  
22 127
- 23 [7] Y.S. Qian, Z.C. Xin, Y.N. Lv, Z.W. Wang, L. Zuo, X. Huang, Y.M. Li, H.B. Xin  
24 2018 Asiatic acid suppresses neuroinflammation in BV2 microglia via modulation of  
25 the Sirt1/NF-kappa B signaling pathway, *Food Funct.* **9** 1048-1057
- 26 [8] W.H. Liu, T.C. Liu, M.C. Mong 2015 Antibacterial effects and action modes of  
27 asiatic acid, *Biomedicine (Taipei).* **5** 16
- 28 [9] Y.Q. Meng, H.B. Cui, L. Li, W.C. Zhang, H.S. Pan, T.T. Yu, W. Li 2018 Synthesis  
29 and antitumor activity evaluation of asiatic acid derivatives as survivin inhibitor, *J*

- 1 *Asian Nat Prod Res.* **20** 1-12
- 2 [10] J.S. Choi, H.S. Kim, H.S. Yoo 2015 Electrospinning strategies of drug-  
3 incorporated nanofibrous mats for wound recovery, *Drug Delivery and Translational*  
4 *Research.* **5** 137-145
- 5 [11] W. Cui, Y. Zhou, J. Chang 2010 Electrospun nanofibrous materials for tissue  
6 engineering and drug delivery, *Sci Technol Adv Mater.* **11** 14-108
- 7 [12] N. Bhardwaj, S.C. Kundu 2010 Electrospinning: a fascinating fiber fabrication  
8 technique, *Biotechnol Adv.* **28** 325-347
- 9 [13] H. Chen, Y. Peng, S. Wu, L.P. Tan 2016 Electrospun 3D Fibrous Scaffolds for  
10 Chronic Wound Repair, *Materials (Basel).* **9** 272-284
- 11 [14] H.N. Kim, Y. Hong, M.S. Kim, S.M. Kim, K.Y. Suh 2012 Effect of orientation  
12 and density of nanotopography in dermal wound healing, *Biomaterials.* **33** 8782-8792
- 13 [15] H. Xu, F. Lv, Y. Zhang, Z. Yi, Q. Ke, C. Wu, M. Liu, J. Chang 2015 Hierarchically  
14 micro-patterned nanofibrous scaffolds with a nanosized bio-glass surface for  
15 accelerating wound healing, *Nanoscale.* **7** 18446-18452
- 16 [16] J.W. Xie, M.R. MacEwan, W.Z. Ray, W.Y. Liu, D.Y. Siewe, Y.N. Xia 2010  
17 Radially Aligned, Electrospun Nanofibers as Dural Substitutes for Wound Closure and  
18 Tissue Regeneration Applications, *Acs Nano.* **4** 5027-5036
- 19 [17] S.F. Chou, D. Carson, K.A. Woodrow 2015 Current strategies for sustaining drug  
20 release from electrospun nanofibers, *Journal of Controlled Release.* **220** 584-591
- 21 [18] Y. Xiao, L.A. Reis, N. Feric, E.J. Knee 2016 Diabetic wound regeneration using  
22 peptide-modified hydrogels to target re-epithelialization, *P Natl Acad Sci USA.* **113**  
23 E5792-E5801
- 24 [19] Y.K. Choi, B.R. Ye, E.A. Kim, J. Kim 2018 Bis (3-bromo-4,5-dihydroxybenzyl)  
25 ether, a novel bromophenol from the marine red alga *Polysiphonia morrowii* that  
26 suppresses LPS-induced inflammatory response by inhibiting ROS-mediated ERK  
27 signaling pathway in RAW 264.7 macrophages, *Biomed Pharmacother.* **103** 1170-1177
- 28 [20] Rachel D. Wilson, Md. Shahidul Islam 2012 Fructose-fed streptozotocin-injected  
29 rat: an alternative model for type 2 diabetes. *Pharmacological Reports.* **64** 129-139
- 30 [21] X.S. Wang, J.F. Ge, E.E. Tredget, Y.J. Wu 2013 The mouse excisional wound



- 1 splinting model, including applications for stem cell transplantation, *Nat. Protoc.* **8**  
2 302-309
- 3 [22] G. Birhanu, H. Akbari Javar, E. Seyedjafari, A. Zandi-Karimi, M. Dusti Telgerd,  
4 2018 An improved surface for enhanced stem cell proliferation and osteogenic  
5 differentiation using electrospun composite PLLA/P123 scaffold, *Artif Cells Nanomed*  
6 *Biotechnol.* **46** 1274-1281
- 7 [23] Z.L. Zhai, S.E. Gomez-Mejiba, D.C. Ramirez 2013 The Nitron Spin Trap 5,5-  
8 Dimethyl-1-pyrroline N-oxide Affects Stress Response and Fate of  
9 Lipopolysaccharide-Primed RAW 264.7 Macrophage Cells, *Inflammation.* **36** 346-354
- 10 [24] Andrews KL, Houdek MT, Kiemele LJ 2015 Wound management of chronic  
11 diabetic foot ulcers: from the basics to regenerative medicine. *Prosthet Orthot Int.* Feb  
12 **39** 29-39
- 13 [25] H.N. Huang, C.Y. Pan, H.Y. Wu, J.Y. Chen 2017 Antimicrobial peptide  
14 Epinecidin-1 promotes complete skin regeneration of methicillin-resistant  
15 *Staphylococcus aureus* infected burn wounds in a swine model, *Oncotarget.* **8** 21067-  
16 21080
- 17 [26] Uzoagu A. Okonkwo and Luisa A. DiPietro 2017 Diabetes and Wound  
18 Angiogenesis, *Int. J. Mol. Sci.* **18** 1419-1434
- 19 [27] C.L. Rettinger, J.L. Fletcher, A.H. Carlsson, R.K. Chan 2017 Accelerated  
20 epithelialization and improved wound healing metrics in porcine full-thickness wounds  
21 transplanted with full-thickness skin micrografts, *Wound Repair and Regeneration.* **25**  
22 816-827
- 23 [28] S. Hazarika, A.O. Dokun, Y. Li, A.S. Popel 2007 Impaired angiogenesis after  
24 Hindlimb ischemia in type 2 diabetes Mellitus - Differential regulation of vascular  
25 endothelial growth factor receptor 1 and soluble vascular endothelial growth factor  
26 receptor 1, *Circulation Research.* **101** 948-956
- 27 [29] X.M. Chen, J.C. Qian, L.T. Wang 2018 Kaempferol attenuates hyperglycemia-  
28 induced cardiac injuries by inhibiting inflammatory responses and oxidative stress,  
29 *Endocrine.* **60** 83-94
- 30 [30] C.C.E. Lan, C.S. Wu, S.M. Huang, I.H. Wu, G.S. Chen 2013 High-Glucose


- 1 Environment Enhanced Oxidative Stress and Increased Interleukin-8 Secretion From  
2 Keratinocytes New Insights Into Impaired Diabetic Wound Healing, *Diabetes*. **62** 2530-  
3 2538
- 4 [31] T. Mustoe 2004 Understanding chronic wounds: a unifying hypothesis on their  
5 pathogenesis and implications for therapy, *Am. J. Surg.* **187** 65-70
- 6 [32] L. Zhang, L. Xu, G. Li, Y. Yang 2018 Fabrication of high-strength mecobalamin  
7 loaded aligned silk fibroin scaffolds for guiding neuronal orientation, *Colloids Surf B*  
8 *Biointerfaces*. **173** 689-697
- 9 [33] Satish Patel, Shikha Srivastava 2019 Mechanistic insight into diabetic wounds:  
10 Pathogenesis, molecular targets and treatments strategies to pace wound healing.  
11 *Biomedicine & Pharmacotherapy* **112** 108615-30
- 12 [34] K. Kaltalioglu, S. Coskun-Cevher 2015 A bioactive molecule in a complex wound  
13 healing process: platelet-derived growth factor, *Int J Dermatol.* **54** 972-977
- 14 [35] R.B. Mateo, J.S. Reichner, J.E. Albina 1994 Interleukin-6 Activity in Wounds, *Am*  
15 *J Physiol.* **266** 1840-1844
- 16 [36] T.J. Fahey, A. Sadaty, W.G. Jones 1991 Diabetes impairs the late inflammatory  
17 response to wound healing, *J Surg Res.* **50** 308-313
- 18 [37] R.E. Mirza, M.M. Fang, W.J. Ennis, T.J. Koh 2013 Blocking Interleukin-1 beta  
19 Induces a Healing-Associated Wound Macrophage Phenotype and Improves Healing  
20 in Type 2 Diabetes, *Diabetes*. **62** 2579-2587
- 21 [38] H.M. Lv, Z.M. Qi, S.S. Wang 2017 Asiatic Acid Exhibits Anti-inflammatory and  
22 Antioxidant Activities against Lipopolysaccharide and D-Galactosamine-Induced  
23 Fulminant Hepatic Failure, *Front Immunol.* **8** 785-801
- 24 [39] K.J. Yun, J.Y. Kim, J.B. Kim, K.W. Lee, S.Y. Jeong 2008 Inhibition of LPS-  
25 induced NO and PGE(2) production by asiatic acid via NF-kappa B inactivation in  
26 RAW 264.7 macrophages: Possible involvement of the IKK and MAPK pathways, *Int*  
27 *Immunopharmacol.* **8** 431-441
- 28 [40] Q. Li, I.M. Verma 2002 NF-kappaB regulation in the immune system, *Nat Rev*  
29 *Immunol.* **2** 725-734
- 30 [41] H.Q. Ding, Y.Y. Xiong, J. Sun, C. Chen, J. Gao, H.X. Xu 2018 Asiatic Acid

- 1 Prevents Oxidative Stress and Apoptosis by Inhibiting the Translocation of alpha-  
2 Synuclein Into Mitochondria, *Front Neurosci-Switz.* **12** 431-441
- 3 [42] D. Wojnicz, D. Tichaczek-Goska, K. Korzekwa, M. Kicia, A. Hendrich 2017 Anti-  
4 enterococcal activities of pentacyclic triterpenes, *Advances in Clinical and*  
5 *Experimental Medicine.* **26** 483-490
- 6 [43] W.H. Liu, T.C. Liu, M.C. Mong 2015 Antibacterial effects and action modes of  
7 asiatic acid, *Biomedicine-Taiwan.* **5** 22-29
- 8 [44] B. Nie, H. Ao, J. Zhou, T. Tang, B. Yue 2016 Biofunctionalization of titanium  
9 with bacitracin immobilization shows potential for anti-bacteria, osteogenesis and  
10 reduction of macrophage inflammation, *Colloids Surf B Biointerfaces.* **145** 728-739
- 11 [45] H.B. Yang, K.T. Nguyen, D.T. Leong, N.S. Tan, C.Y. Tay 2016 Soft Material  
12 Approach to Induce Oxidative Stress in Mesenchymal Stem Cells for Functional Tissue  
13 Repair, *ACS Appl. Mater. Interfaces.* **8** 26591-26599
- 14 [46] R. Costa, R. Negro, I. Valente, A. Castela, D. Duarte, L. Guardao, P.J. Magalhaes,  
15 J.A. Rodrigues, J.T. Guimaraes, P. Gomes, R. Soares 2013 Xanthohumol Modulates  
16 Inflammation, Oxidative Stress, and Angiogenesis in Type 1 Diabetic Rat Skin Wound  
17 Healing, *J Nat Prod.* **76** 2047-2053
- 18 [47] K. Kaltalioglu, S. Coskun-Cevher 2015 A bioactive molecule in a complex wound  
19 healing process: platelet-derived growth factor, *Int. J. Dermatol.* **54** 972-977
- 20 [48] H.N. Hasmad, M.R. Yusof, Z.R. Mohd Razi, R.B. Haji Idrus, S.R. Chowdhury  
21 2018 Human amniotic membrane with aligned electrospun fiber as scaffold for aligned  
22 tissue regeneration, *Tissue Eng Part C Methods.* **24** 368-378
- 23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15

16 Figure


17



18


19 Figure 1. SEM images of the aligned porous PLLA (A<sub>1</sub>, A<sub>2</sub>), 10 AA-PL (B<sub>1</sub>, B<sub>2</sub>), 30  
 20 AA-PL (C<sub>1</sub>, C<sub>2</sub>) scaffolds; The insert of each panel in Figure A<sub>3</sub>-C<sub>3</sub> showed the water  
 21 droplet sat on the surface of each scaffold.

22



1

2 Figure 2. (A) The ultraviolet (UV) ray's absorbance curve of AA; (B) The extract  
3 solution of PLLA, 10 AA-PL and 30 AA-PL scaffolds. (C)The cumulative release  
4 amount and (D) cumulative release percentage of AA released from 10 AA-PL and 30  
5 AA-PL scaffolds within 7 days.




1

2 Figure 3. The gene expression levels of proinflammatory cytokines: IL-1 $\beta$ (A), TNF-  
 3  $\alpha$ (B) and IL6(C) in LPS-induced inflammatory RAW 264.7 macrophage cells while the  
 4 RAW 264.7 cells were co-cultured with PL, 10 AA-PL and 30 AA-PL (D) Live/Dead  
 5 staining was performed to detect the cell viability of HaCat cells cultured with different  
 6 treatments: (a) non-treated (BL); (b) only treated with 500  $\mu$ M H<sub>2</sub>O<sub>2</sub> (Ctrl); (c-e) HaCat  
 7 cells cultured on the PLLA (c), 10 AA-PL(d), 30 AA-PL (e) scaffolds and stimulated  
 8 by 500  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 2 hours (scale bar = 400  $\mu$ m), respectively. (E) Quantified the ratio  
 9 of Live/dead cells (F)The corresponding cell proliferation of HaCat cells cultured with

1 different treatments as described in Figure 3D. (\* P < 0.05; \*\*P < 0.01; \*\*\* P < 0.001) View Article Online  
DOI: 10.1039/C9TB01327J

2



3

4 Figure 4. *E. coli* (A) and *S. aureus* (C) were co-cultured with the PLLA, Penicillin (25


5 ug/mL), 10 AA-PL, 30 AA-PL scaffolds, then diluted to 10<sup>6</sup> and coated the bacterial

6 solution on agar-containing LB solid medium (scale bar = 2 mm); The corresponding

7 statistics of the total number of the *E. coli* (B) and *S. aureus* (D) colonies in the different

8 treated groups. (\* P < 0.05 ; \*\*P < 0.01 ; \*\*\* P < 0.001)

9



1

2 Figure 5. (A) Schematic diagram of the establishment of the non-contractile diabetic

3 wound model ; (B) Overview of the size change of the wounds in different groups (Ctrl,

4 PLLA, 10 AA-PL, 30 AA-PL) on day 0, 3, 7 and 15 after surgery (scale bar = 2 mm);

5 (C) Wound trace for each treatment group on day N ( red area represented the wound

6 area at day N, N = 3, 7 and 15) after surgery relative to day 0 (blue area represented the

7 wound area at day 0) *in vivo*. (D) Statistics analysis of the wound healing rate of PL, 10

8 AA-PL, 30 AA-PL treated groups on day 0, 3, 5, 7, 11, 13, 15 after surgery. (\* P &lt; 0.05;


9 \*\*P &lt; 0.01; \*\*\* P &lt; 0.001)

10

11

12





3


4 Figure 6. (A) The gene expression levels of IL-1 $\beta$  (B), IL6 and TNF- $\alpha$  in the wound

5 tissues of different groups at day 7 after operation, respectively. (B) The gene

6 expression levels of IL-1 $\beta$ , TNF- $\alpha$  and IL6 in the wound tissues of different groups at

7 day 15 after operation, respectively. (\*  $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\*  $P < 0.001$ )

8



1

2 Figure 7. (A) Masson trichrome staining of the wounds tissues in the four groups (Ctrl,


3 PLLA, 10 AA-PL and 30 AA-PL) at day 7 and day 15 after surgery (the edge of epithelium was pointed by the red arrows; scale bar = 2 mm). (B-C) Statistical analysis

4 of re-epithelialization efficiency in different treated groups at day 7 (B) and day 15 (C)


5 after operation. (\*  $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\*  $P < 0.001$ )

6

7



1  
2 Figure 8. (A) CD31 immunofluorescence staining of the wounds tissue in different  
3 groups at 7 days after surgery, CD31 positive cells (Green, marked with red arrow)  
4 represents angiogenesis, cell nucleus (Blue) (scale bar = 50 μm); (B) Quantification  
5 analysis of CD31-positive vessels per high-power field (HPF) at day 7. (\* P < 0.05; \*\*P  
6 < 0.01; \*\*\* P < 0.001)



8  
9 Figure 9. (A) Masson's trichrome staining of collagen fibers (blue) in the wound sites  
10 in the different groups (Ctrl, PLLA, 10 AA-PL and 30 AA-PL) at 15 days post-surgery  
11 (scale bar = 100 μm). (B) Quantification of the collagen-positive pixels per high-power  
12 field at day 15. (\* P < 0.05; \*\*P < 0.01; \*\*\* P < 0.001)

1

2 Table

3

Table 1. Primer Sequence List

Gene	Primer sequences
Actin-F	5'-GTACGCCAACACAGTGCTG-3'
Actin-R	5'-CGTCATACTCCTGCTTGCTG-3'
IL-1 $\beta$ -F	5'-GCAACTGTTCTGAACTCAACT-3'
IL-1 $\beta$ -R	5'-ATCTTTTGGGGTCCGTCAACT-3'
IL-6-F	5'-TAGTCCTTCCTACCCCAATTTC-3'
IL-6-R	5'-TTGGTCCTTAGCCACTCCTTC-3'
TNF- $\alpha$ -F	5'-TTCCGAATTCAGTGGAGCCTCGAA-3'
TNF- $\alpha$ -R	5'-TGCACCTCAGGGAAGAATCTGGAA-3'

4

5

6

7

8

9

10

11

12

13

14

15

16

